<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237701</url>
  </required_header>
  <id_info>
    <org_study_id>2000026771</org_study_id>
    <nct_id>NCT04237701</nct_id>
  </id_info>
  <brief_title>Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System</brief_title>
  <acronym>Yale-HF</acronym>
  <official_title>Retrospective and Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System Via a Live Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Yale HF Registry is a live EHR based registry that allows for retrospective and real-time
      monitoring of Heart Failure case across the Yale New Haven Health System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Electronic Health Records based registries can be an important resource for precision
      medicine delivery by understanding the population burden of chronic diseases such as heart
      failure. These registries can allow for a deeper understanding of gaps in guideline
      recommended therapies among patients who are under the purview of large, integrated
      Therefore, we have created a live registry within the integrated Yale New Haven Health
      System—the Yale Heart Failure Registry—that includes all patients with a diagnosis of HF and
      has detailed information about demographics, comorbidities, laboratories, imaging,
      medications, and clinical outcomes (including hospital readmissions). The registry is updated
      daily and can be queried for clinically relevant questions aimed at quality improvement.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>10 years</time_frame>
    <description>Heart Failure hospitalizations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Doses of therapies that comprise guideline directed medical therapy</measure>
    <time_frame>10 years</time_frame>
    <description>Appropriate use of guideline recommended therapies. This will include doses of beta blockers, ACE inhibitors, ARBs, ARNI, SGLT2i, ICD use.</description>
  </primary_outcome>
  <enrollment type="Anticipated">40000</enrollment>
  <condition>Heart Failure</condition>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <condition>Heart Failure NYHA Class IV</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Retrospective and Real-Time Monitoring of Heart Failure Across the Yale New Haven Health
        System Via a Live Registry
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Seen within the Yale New Haven Health System

          -  Diagnosis of heart failure

        Exclusion Criteria:

          -  Age&lt;18
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Nihar Desai, MD MPH</last_name>
    <role>Study Director</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tariq Ahmad, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tariq Ahmad, MD MPH</last_name>
    <phone>(203) 843-1667</phone>
    <email>Tariq.ahmad@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nihar Desai, MD MPH</last_name>
    <phone>203-767-6399</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale New Haven Health System</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tariq Ahmad, MD MPH</last_name>
      <phone>203-843-1667</phone>
      <email>tariq.ahmad@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nihar Desai, MD MPH</last_name>
      <phone>2037676399</phone>
      <email>nihar.desai@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tariq Ahmad, MD MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nihar Desai, MD MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, Duffy CI, Hill CL, McCague K, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Butler J. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019 May 21;73(19):2365-2383. doi: 10.1016/j.jacc.2019.02.015. Epub 2019 Mar 4.</citation>
    <PMID>30844480</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 17, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data is on patients seen at Yale New Haven Health system and will be used for quality improvement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

